Karaganda Pharmaceutical Complex

Karaganda Pharmaceutical Complex (KPC) is a leading biopharmaceutical company in Kazakhstan, recognized as the country's first high-tech facility dedicated to the production of complex biological medicines. The company operates a modern, GMP-certified manufacturing plant capable of advanced processes including fill-finish and lyophilization for vaccines and monoclonal antibodies. KPC gained significant international prominence for its role in the localized production of the Sputnik V COVID-19 vaccine through a strategic partnership with Russia's Gamaleya Institute. Beyond vaccines, the company focuses on producing biosimilars for oncology, hematology, and rare diseases, collaborating with international biotech firms like Biocad and Generium. As a critical component of Kazakhstan's national drug security strategy, KPC ensures domestic access to innovative and affordable biotechnological therapies.